Alvotech Champions Switching Data As Clock Ticks On Adalimumab Filing
Top-Line Results Announced In Major Switching Study; Bioequivalence Demonstrated
Before the month is out, Alvotech hopes to hear back from the US FDA for its AVT02 high-concentration 100mg/ml biosimilar adalimumab candidate. The Icelandic firm, which remains embroiled in litigation with originator AbbVie, has reported top-line results from its key switching study.
